New fluoroquinolones (FQ) may possibly be used as alternative therapeutic options for Staphylococcus aureus infections. Our objectives were: (1) to define the in vitro activities of seven FQs in a collection of 434 methicillin-susceptible and 457 methicillin-resistant S. aureus from 23 European university hospitals; (2) to characterise the prevalence of mutations in the grlA and gyrA genes in all ciprofloxacin-resistant (n = 433) isolates of S. aureus; (3) to determine the percentage of ciprofloxacinresistant S. aureus strains with measurable quinolone efflux. Methods: (1) The in vitro activities of different FQs were determined by microdilution tests. (2) PCR-amplified DNA was sequenced. (3) Ciprofloxacin minimum inhibitory concentrations (MIC) were determined in the presence and absence of reserpine, which inhibits efflux pumps. Results: (1) Irrespective of the methicillin resistance of the isolates, sitafloxacin and clinafloxacin showed the best in vitro activities. (2) All ciprofloxacin-resistant isolates exhibited GrlA alterations, namely Ser-80CPhe or Tyr or Glu-84CLys or Ala-116CGlu or Pro or a combination of Ser-80CPhe and Glu-84CVal. These alterations in GrlA were combined with alterations in GyrA, namely Ser-84CLeu or Lys or Glu-88CLys or Val. 
Introduction
Fluoroquinolones (FQs) are inhibitors of DNA topoisomerases, mainly DNA gyrase and topoiso-0928-8244 / 99 / $20.00 ß 1999 Federation of European Microbiological Societies. Published by Elsevier Science B.V. All rights reserved. PII: S 0 9 2 8 -8 2 4 4 ( 9 9 ) 0 0 1 4 5 -5 merase IV. In most Gram-negative bacteria, DNA gyrase is the primary target for FQs, but in Grampositive micro-organisms, topoisomerase IV seems to be the main target for most FQs. Nevertheless, target speci¢cities can alter with various drugs, and some molecules, such as spar£oxacin, have been shown to mainly target gyrase in some Gram-positive bacteria [1^4] .
As part of the topoisomerase reaction mechanism, gyrase and topoisomerase IV transiently break the DNA backbone and pass a double strand of DNA through those breaks. The quinolones trap an intermediate during this reaction, leaving the topoisomerases attached to the DNA as part of drug-enzyme-DNA complexes in which the DNA probably remains broken. The number of such complexes formed with gyrase correlates well with the extent to which overall DNA synthesis is inhibited, consistent with the idea that the complexes block the movement of DNA through the DNA replication machinery. Cell death apparently results from release of double-stranded DNA breaks from drug-enzyme-DNA complexes which are located throughout the chromosome. Quinolone-resistant mutations are expected to prevent complex formation, since they allow DNA synthesis and cell growth to occur in the presence of quinolone [2, 5, 6] .
Mutations associated with increased resistance to quinolones in Staphylococcus aureus have been documented in conserved regions of grlA and grlB, genes encoding DNA topoisomerase IV, and in conserved regions of gyrA and gyrB, genes encoding DNA gyrase. These conserved regions are referred to as the quinolone-resistance-determining region (QRDR). Mutations in grlA and gyrA are the most frequently encountered changes associated with quinolone resistance in S. aureus. In addition to these mutations, S. aureus also have multi-drug e¥ux pumps like NorA that contribute to decreased £uoroquinolone susceptibility [1,3,4,7^9] .
Because of the inherent limitations of cipro£oxa-cin and other available quinolones in the treatment of staphylococcal infections, there is a need for the development of new quinolones with increased antistaphylococcal potency. Clina£oxacin, gati£oxacin, levo£oxacin, moxi£oxacin, trova£oxacin, and sita£oxacin are recently developed newer £uoroquino-lones with a broad antimicrobial spectrum and minimal inhibitory concentrations (MICs) within clinically achievable levels in blood for some S. aureus isolates that are resistant to cipro£oxacin [2,5,6,10^12] . The clinical utility of these newer £uo-roquinolones for the treatment of infections caused by cipro£oxacin-resistant Gram-positive cocci has yet to be established, however.
The purposes of the present investigation were:
1. to de¢ne the in vitro activities of seven FQs in a collection of 434 methicillin-susceptible and 457 methicillin-resistant S. aureus from 20 European university hospitals; 2. to characterise the prevalence and manner of mutations in the grlA and gyrA genes in all cipro£oxacin-resistant (n = 433) isolates of S. aureus, and 3. to determine the percentage of cipro£oxacin-resistant S. aureus strains with measurable quinolone e¥ux.
Materials and methods

Bacterial isolates
The in vitro activity of seven FQs was tested against 434 methicillin-susceptible S. aureus (MSSA) and 457 methicillin-resistant S. aureus (MRSA) isolates deriving from 23 university hospitals in 13 European countries. These isolates were collected between April 1997 and July 1998. The strains originated from patients with bacteraemia, nosocomial pneumonia, wound infections, or urinary tract infections. Only one isolate per patient, which was considered clinically signi¢cant according to local criteria, was submitted. Upon receipt, isolates were subcultured onto blood agar to ensure purity. Isolate identity was con¢rmed, if necessary, using a Vitek system (bioMërieux, France).
From these 891 isolates, all cipro£oxacin-resistant strains (n = 433) (minimum inhibitory concentration (MIC) s 4 mg l 31 ), comprising 420 MRSA and 13 MSSA were analysed for mutations in the QRDR of the grlA and gyrA genes.
Participating countries and hospitals
These included Austria (Krankenhaus der Elisa- 
Susceptibility testing
Antimicrobial susceptibility testing of isolates was performed using a reference broth microdilution method according to the guidelines recommended by the National Committee for Clinical Laboratory Standards (NCCLS) [13] , with an inoculum of approximately 10 5 cfu ml 31 and doubling dilutions of FQs ranging from 9 0.008 to s 16 mg l 31 . The seven FQs were provided by the respective manufacturers.
Polymerase chain reaction, oligonucleotide primers and sequencing
Protocols for the ampli¢cation and subsequent sequencing of grlA and gyrA have been described previously [12] .
In£uence of reserpine on cipro£oxacin MIC values
MICs of cipro£oxacin for all cipro£oxacin-resistant S. aureus strains were determined, as described by Neyfakh et al. [14, 15] , using microdilution plates containing 1:2 serial dilutions of the antibacterial drugs in 100 Wl of LB medium (inoculum, 2U10 5 exponential-phase cells, incubation, 12 h at 37³C). All experiments were carried out in the absence or presence of reserpine (20 mg l 31 ). After the incubation period bacterial growth was assessed by observing medium turbidity. For each isolate tested a MIC value ratio was calculated by dividing the obtained values in the absence of reserpine by the values obtained in the presence of reserpine.
Results and discussion
In vitro activities of di¡erent FQs
The di¡erences between the in vitro potencies of the seven FQs tested against MSSA were smaller than those against MRSA. This study con¢rms a previous investigation [12] and extends earlier analyses since this is one of the few comparisons of the in vitro activities of seven FQs against current S. aureus isolates from European university hospitals.
Prevalence and manner of GrlA and GyrA alterations in cipro£oxacin-resistant S. aureus
The present study constitutes one of the largest series of cipro£oxacin-resistant S. aureus strains (n = 433) from distinct geographic areas for which partial sequences of the grlA and gyrA gene loci have been obtained.
Within GrlA six single or combined alterations were obtained: Ser-80CPhe or Tyr, Glu-84CLys, Ala-116CGlu or Pro and the combination of Ser80CPhe with Glu-84CVal.
Within GyrA four single alterations were obtained: Ser-84CLeu or Lys and Glu-88CLys or Val. Table 1 illustrates the combinations of alterations in GrlA and GyrA that were found in the cipro£ox-acin-resistant S. aureus population. In addition the percentage of appearance is given. As illustrated, the combination of Ser-80CPhe in GrlA with Ser84CLeu in GyrA is by far the most prevalent combination of alterations in DNA topoisomerase IV and gyrase in the European cipro£oxacin-resistant S. aureus population. This current European overview of mutations involved in FQ resistance demonstrates that only a limited number of classical mutations in grlA and gyrA contributed to resistance in clinical isolates. The present study con¢rms previous investigations [1,12,16^19] and extends earlier analyses since this is one of the few investigations in which a large population from European university hospitals was screened for alterations in GrlA and GyrA.
Analysis of percentage of cipro£oxacin-resistant S. aureus strains with measurable quinolone e¥ux
The e¥ux of £uoroquinolones from the cell mostly results in a lower level of resistance than that seen in grlA or gyrA mutants. Since most experiments concerning NorA in S. aureus only used one clinical £uoroquinolone-susceptible strain, S. aureus SA-1199, it is possible that e¥ux pumps are important only in a limited number of £uoroquinolone-susceptible and -resistant S. aureus isolates [7, 14, 15] . The plant alkaloid reserpine has been shown to inhibit multidrug transporters like NorA [14, 15] , increasing the intracellular concentration of £uoroquinolones, thus potentially lowering MIC values.
The presence of reserpine (20 mg l 31 ), which by itself does not a¡ect the growth of S. aureus [14] , in the incubation medium resulted in up to four-fold decreases in cipro£oxacin MIC values in 139 out of 433 (30.3%) cipro£oxacin-resistant S. aureus isolates. However, in the rest of the isolates tested reserpine had no e¡ect on the MIC values, resulting in MIC ratios of 1 for these strains.
For this there could be several possible explanations. Strains could vary in the extent to which reserpine is able to block NorA or other e¥ux transporters because of reserpine resistance, as has been reported for Bmr, a related transporter in Bacillus subtilis [20] . Reserpine could also have varying e¡ects because the expression of NorA and/or other as yet unidenti¢ed e¥ux transporters could vary due to regulatory mutations in the region 5P to norA or to the genes for other reserpine-sensitive transporters or may be localised to other regions of the chromosome, as appears to be the case for a previously reported inducible mutant [9] .
The response to reserpine and the reduction in susceptibility do not correlate with the determined MIC and IC 50 values in the absence of reserpine or with mutations within the grl or gyr gene loci, as has been shown by us previously [21] . Furthermore, the observed inhibitory e¡ect is not dependent on £uo-roquinolone susceptibility (data not shown).
Thus, reserpine as an inhibitor of multi-drug e¥ux pumps seems to increase the intracellular concentra- Table 1 Combinations of alterations in GrlA and GyrA that were found in the cipro£oxacin-resistant S. aureus population (n = 433) and the percentage of appearance GrlA GyrA (in percent)
Ser-80CPhe Ser-84CLeu 56 Ser-80CPhe
Glu-88CLys 21 Ser-80CTyr
Ser-84CLeu 6 Ser-80CTyr
Glu-88CLys 6 Glu-84CLys
Ser-84CLeu 1 Glu-84CLys
Glu-88CLys 5 Ala-116CGlu
Ser-84CLys 1 Ala-116CPro
Glu-88CVal 1 Ser-80CPhe+Glu-84CVal
Ser-84CLeu 3 tion of cipro£oxacin in one fourth to one third of the strains tested. This might have therapeutic consequences, if in those isolates an inhibitor of e¥ux pump activity could be combined with a new quinolone. Reserpine is toxic for man in those concentrations which are needed to inhibit e¥ux activity. Therefore other e¥ux inhibitors are needed. In summary, clina£oxacin and sita£oxacin are two new £uoroquinolones with excellent anti-staphylococcal activity. The combination of Ser-80CPhe in GrlA with Ser-84CLeu in GyrA is by far the most prevalent combination of alterations in DNA topoisomerase IV and gyrase in the European cipro£ox-acin-resistant S. aureus population. In one fourth to one third of the cipro£oxacin-resistant strains tested, reserpine slightly decreased MIC values of cipro£ox-acin, suggesting the existence of multi-drug e¥ux pumps which seem to decrease the intracellular cipro£oxacin concentration. New FQs, perhaps in combination with e¥ux pump inhibitors, might play a role in the treatment of S. aureus infections.
